Ataxion secures Series A Financing from Atlas Venture and Biogen Idec
Ataxion, a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic diseases, has secured Series A financing commitments totaling $17 million from Atlas Venture and Biogen Idec. Based in Cambridge, Massachusetts, the company’s lead program is focused on a group of orphan genetic disorders termed hereditary ataxias.
18 March 2014•4 mins read
